Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00205842 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | PHASE3 | COMPLETED | 660 | — | — | Jun 1, 2004 | Dec 1, 2005 | Jan 11, 2016 | 1 | United States |
| NCT00388401 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | PHASE3 | COMPLETED | 510 | — | — | Jan 1, 2002 | Jun 1, 2003 | Jul 20, 2015 | 1 | United States |
| NCT00388479 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus | PHASE3 | COMPLETED | 666 | — | — | Dec 1, 2001 | Nov 1, 2003 | Jul 20, 2015 | 1 | United States |
| NCT00388258 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | PHASE3 | COMPLETED | 451 | — | — | Mar 1, 2001 | Dec 1, 2002 | Aug 22, 2017 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| alvimopan | DRUG | - |
Inclusion Criteria: * Subject is scheduled for a partial small/large bowel resection with primary anastomosis; all procedures must be performed completely by open laparotomy. * Subject is scheduled to receive primary postoperative pain management with intravenous (i.v.) patient-controlled analgesia...